Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00235820 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 271
- Enrollment target
NCT00235820 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 271 participants.
The verdict
NCT00235820, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 271 participants
- Enrollment target
Study Summary
Placebo-Controlled Study Comparing the Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects with Moderate to Severe Chronic Plaque Psoriasis
Interventions
- DRUG MTX
- DRUG adalimumab
- DRUG placebo adalimumab, placebo MTX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 271 participants |
| Start Date | 2005-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00235820
The ClinicalTrials.gov registry entry for NCT00235820 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 271 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which MTX is the first listed.
NCT00235820 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00235820 about?
NCT00235820 is a clinical study titled "Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis". Placebo-Controlled Study Comparing the Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects with Moderate to Severe Chronic Plaque Psoriasis
What is the current status of trial NCT00235820?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 271 participants. The study started on 2005-07.
What interventions are being tested in trial NCT00235820?
The interventions under investigation include: MTX (DRUG), adalimumab (DRUG), placebo adalimumab, placebo MTX (DRUG).
Who is sponsoring clinical trial NCT00235820?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.